.png)
The peptide and oligonucleotide CDMO market has been expanding rapidly owing to the preference of pharmaceutical and biotechnology organizations to engage third-party drug development and manufacturing services. The increasing demand for RNA drugs, GLP-1 drugs, and precision drugs has driven the trend. In view of the rising complexity of drug molecules, the need for contract development and manufacturing organizations (CDMOs) is clearly apparent.
What Is a Peptide and Oligonucleotide CDMO?
A peptide and oligonucleotide CDMO is an organization that helps pharmaceutical and biotechnology companies to develop, manufacture, test, and commercialize their peptide and nucleic acid-based therapies. Instead of building an expensive manufacturing facility, a drug manufacturer may decide to partner with a contract development and manufacturing organization to benefit from new technology, expertise, and regulatory services. Such firms are essential in the process of bringing innovative drugs into the market through consistent product quality and regulatory compliance. With the increasing need for peptides and RNA medicines, peptide and oligonucleotide CDMOs have emerged as a key partner for firms in the development process.
Understanding CDMO Services
A contract development and manufacturing organization offers end-to-end services during the entire drug development life cycle. A peptide CDMO is a company specializing in the synthesis of peptides, whereas an oligonucleotide CDMO is a company specializing in the manufacturing of RNA- and DNA-based treatments. The services offered by these companies include process development, analytical services, formulation services, technology transfer, GMP manufacturing, quality assurance, regulatory services, and commercial manufacturing. Pharmaceutical outsourcing helps firms get access to such services without investing in facilities themselves.
Key Stats and Takeaways
The peptide and oligonucleotide CDMO market was valued at USD 2.29 billion in 2025. The peptide and oligonucleotide CDMO market is projected to grow at a CAGR of 10.70% from 2026 to 2034.
- Peptide and oligonucleotide CDMOs are increasingly becoming strategic partners for pharma companies.
- The growth in RNA-based therapies and GLP-1 drugs is driving outsourcing trends.
- Artificial intelligence and automation are helping enhance manufacturing process efficiencies.
- The Asia Pacific region is poised to be a key production hub.
- GMP facilities and advanced synthesis technology investments will fuel market growth.
Key Factors Driving the Peptide and Oligonucleotide CDMO Market
There are several industry trends that are propelling the growth of the peptide and oligonucleotide CDMO market. The pharmaceutical industry is putting in greater effort in the development of biologics, targeted therapies, and genetic medicine, which is driving up the need for partners in manufacturing. In addition, there has been an increase in research activities, the number of clinical trials, and regulatory demands, all of which are driving outsourcing of complex manufacturing activities. The CDMO has the flexibility, technical expertise, and production capabilities to help in clinical and commercial manufacturing. The capability of CDMOs to deliver integrated development services enables drug developers to accelerate the process and mitigate the associated risks.
Rising Demand for Peptide Therapeutics
Peptide therapeutics are finding widespread acceptance. This is because of their high selectivity, better safety profile, and treatment possibilities for various chronic ailments. Medicines based on peptides are being used to treat diabetes, obesity, cancers, hormonal disorders, and cardiac ailments, among others. Commercial success of GLP-1 receptor agonists has only increased the need for the production of peptides. With the development of newer peptide drugs by pharmaceutical companies, there is a need for professional CDMOs that can ensure high-quality peptide production.
Expansion of RNA-Based Therapeutics
The rapid growth of RNA therapeutics is creating an increasing number of opportunities in specialized manufacturing. Novel methods, including mRNA, siRNA, antisense oligonucleotides, and gene editing technology, are revolutionizing the approach to treating genetic diseases, infections, and cancer. Such novel oligonucleotide medications need a complex process for their manufacturing that guarantees high-quality products. Precision medicines have gained growing popularity, resulting in increased demand for tailor-made medications; therefore, experienced CDMOs will play a crucial role in this sphere. Further innovations in gene therapy manufacturing are expected to contribute to the ongoing growth of the market.
Why Pharmaceutical Companies Are Outsourcing to CDMOs?
Outsourcing is no longer just an activity but rather a strategy adopted by pharmaceutical companies to reduce costs, save time, and ensure more efficient process management. Building and operating modern facilities demands a large amount of money as well as special equipment and specialists. By using pharmaceutical outsourcing, a company gets immediate access to professional scientific staff and manufacturing capabilities.
They also make the development of the drugs faster by providing process optimization, analysis, scale-up, validation, and technology transfer services under one roof. This helps in minimizing compliance problems while maintaining consistency in the quality of the products because of their GMP production capabilities and global regulations knowledge.
Another major benefit that CDMOs bring is flexible contract manufacturing capability. Companies can increase or decrease the level of production based on the progress of the trials or the needs in the market without having to invest in their own infrastructure. With such flexibility along with the advanced technologies and pharmaceutical development services, inventors are able to focus more on research than production.
Emerging Technologies Transforming CDMO Manufacturing
Innovation is transforming the manufacturing of peptides and oligonucleotides by increasing efficiencies, scalability, and reliability. Today's CDMOs are leveraging technology such as advanced process controls and automation in order to achieve better quality of products while cutting down on production times and costs.
Some manufacturers have moved away from batch processing to continuous processing, which increases efficiency. The single-use bioprocessing system ensures minimal chances of contamination while being flexible enough to switch production quickly from one product to another. Flow chemistry has also become popular, mainly because it increases the level of control over the complex process of synthesis and enhances manufacturing efficiency.
Digital Transformation in Pharmaceutical Manufacturing
AI in pharmaceutical manufacturing is aiding CDMOs in optimizing the manufacturing processes by analyzing process data and predicting possible issues. Through continuous manufacturing, pharmaceutical automation, digital quality control, and real-time data analytics, it becomes easy to monitor the manufacturing process without going against regulatory laws. Smart manufacturing not only makes production efficient but also ensures fast commercialization.
GLP-1 and RNA Therapeutics Are Creating New Market Opportunities
Increasing usage of GLP-1-based therapies opens up numerous opportunities for peptide manufacturers globally. The increase in demand for semaglutide manufacturing, as well as for the production of tirzepatide, has led pharmaceutical companies to invest in expanding their manufacturing capacity to meet the needs associated with the rising number of obesity drugs and diabetes medications. These therapies demand highly complex peptide synthesis, which makes it imperative for pharmaceutical companies to use the services of the CDMOs that have considerable experience in working with peptides and can provide them with quality products.
Additionally, further development of RNA-based therapeutics is leading to the need for highly specialized oligonucleotide manufacturing capabilities. With innovations in this area, the demand for specialized CDMO services is expected to continue growing consistently. For further reading on related industry developments, readers may refer to the GLP-1 market and antisense and RNAi therapeutics market.
Regional Insights: Which Markets Are Leading Growth?
The peptide and oligonucleotide CDMO market is growing across the leading pharmaceutical regions, owing to rising funding in research, manufacturing, and advanced medicines. While North America is leading the global market at present, Asia Pacific is the fastest-growing region because of growing production capacity and competitive manufacturing costs. Europe is another key market for this industry due to its pharmaceutical industry, regulations, and innovation in medicine. All these trends will further drive the global pharmaceutical manufacturing market and encourage greater biotechnology outsourcing across the industry.
North America
North America accounted for the largest market share due to its developed biotech ecosystem, high spending on pharmaceutical research & development, and presence of the major drug manufacturers. High regulatory standards, ongoing innovation, and state-of-the-art manufacturing infrastructure provide this region with an advantage in drug manufacturing processes. Increasing numbers of peptides and RNA therapies that move into clinical trials boost the North America CDMO market.
Asia Pacific
The Asia Pacific CDMO market is predicted to show the highest growth rate in the forthcoming years. China, India, and South Korea are increasing their GMP production capacities through launching new facilities and upgrading manufacturing technologies. Competitively low production costs, highly qualified scientific staff, and an improved regulatory environment attract multinational pharmaceutical companies looking for dependable manufacturing partners. Cost advantages, a high scientific talent pool, and advanced regulation are making the region favorable for biotechnology outsourcing.
Competitive Landscape
The level of competition in the peptides and oligonucleotides CDMO market is rising due to increased manufacturer capabilities in response to rising global demand. Key companies are investing in capacity building, adopting advanced peptide synthesis technologies, improving GMP facilities, and forming partnerships to build their market positions. Companies have also acquired other firms to expand their services and geographical presence.
The prominent players in the industry, such as Bachem, PolyPeptide Group, CordenPharma, Thermo Fisher Scientific, WuXi AppTec, Cambrex, Merck KGaA, and EUROAPI, are continuing to improve their production capacity through innovation in technology. The firms are also increasingly partnering with drug companies to develop the emerging pipeline of peptide and oligonucleotide drugs.
Future Outlook of the Peptide and Oligonucleotide CDMO Market
It is projected that the peptide and oligonucleotide CDMO market will experience growth through 2034 due to innovation in the pharmaceutical industry and demand for manufacturing services. AI technology in manufacturing, automation, and digitalization will enhance productivity while ensuring quality of production. Growth in the use of personalized medicine, RNA therapeutics, and peptides will lead to more outsourcing needs in the pharmaceutical industry.
With rising investments in pharmaceutical research and development, CDMOs that have advanced manufacturing technology, regulatory knowledge, and scalability in production are expected to succeed in this sphere in the long run. Expansion of manufacturing capacities globally and collaboration are predicted to create opportunities in the market. For more information about the market size, forecast, regional trends, and competition in this market, explore the peptide and oligonucleotide CDMO market report by Polaris Market Research. Related developments can be found in the gene therapy market, pharmaceutical manufacturing market, and contract research organization (CRO) market reports.
.png)
